ILuye Pharma Group namuhla imemezele ukuthi inkampani engaphansi kwayo iLuye Pharma Switzerland AG yenze izivumelwano ne-Exeltis Pharma México, SA de CV kanye ne-Exeltis Pharmaceuticals Holding, SL (Exeltis), lapho inkampani inikeza i-Exeltis amalungelo akhethekile okudayisa i-Rivastigmine Multi-Day Transdermal Patch. (Rivastigmine MD) eMexico nasePoland.

I-Rivastigmine MD iyisiqeshana se-Rivastigmine esisha samasonto onke sokwelapha ukuwohloka komqondo okumaphakathi kuya kokumaphakathi okuhlobene nesifo i-Alzheimer's. Umuthi wathuthukiswa ngu-Luye Pharma endaweni yawo ye-proprietary transdermal patch platform futhi uthole ukugunyazwa kokumaketha emazweni amaningana aseYurophu.

UBruno Delie, iMenenja Jikelele ye-Luye Pharma (Switzerland), uthe: “I-Exeltis inenkundla yezentengiselwano ephelele kanye nolwazi oluningi nolwazi oluningi endaweni yokwelapha yesistimu yezinzwa emaphakathi (CNS). Sibheke ngabomvu ukusebenzisana ne-Exeltis ukuze sibhekane nezidingo ezingafinyeleleki zokukhulisa imiphakathi yeziguli ezine-Alzheimer, kanye nokubasiza ukuba balawule kangcono lesi sifo.” Iyingxenye ye-Insud Pharma Group, enekomkhulu eSpain, i-Exeltis yinkampani yamazwe ngamazwe eyenza imithi enemikhiqizo edayiswa njengamanje emazweni angu-44 emhlabeni jikelele. Le nkampani inolwazi olunzulu lwezifo ze-CNS kanye nokusebenza kwebhizinisi okuqinile eYurophu naseLatAm.

I-Luye Pharma isheshisa ukuthuthukiswa nokudayiswa kwe-Rivastigmine MD emakethe yomhlaba. Ukuthengisa ezimakethe zase-Europe kufakwa amanxusa wendawo kanye nozakwethu benkampani. Ngaleso sikhathi, amalungelo akhethekile okuthuthukiswa nokudayisa kwe-Rivastigmine MD e-Japan anikezwe uzakwethu wase-Japan. U-Luye Pharma futhi uhlela ukusheshisa ukuthengiswa kwe-Rivastigmine MD emazweni amaningi asathuthuka kanye nezimakethe ezikhulayo emhlabeni jikelele.

Isifo i-Alzheimer's yisifo se-neurodegenerative esingahlehliseki esidala ukwehla okuqhubekayo kwenkumbulo nezinye izici zengqondo. I-Dementia ehlotshaniswa nesifo i-Alzheimer iwuhlobo oluvame kakhulu lokuwohloka komqondo, olubalelwa ku-60-80% wazo zonke izimo[i]. Kulinganiselwa ukuthi kunabantu abangaphezu kwezigidi ezingu-50 abaphila nokuwohloka komqondo emhlabeni wonke, okuyisibalo esihlelwe ukuba sibe ngaphezu kokuphindwe kathathu, siye ezigidini ezingu-152 ngo-2050[ii].

Ukuqhubekela phambili kokuthuthukiswa kwemithi emisha emkhakheni wesifo i-Alzheimer kuhamba kancane, futhi okwamanje kunenani elilinganiselwe kakhulu lezindlela zokwelapha ezitholakalayo ezigulini. I-Rivastigmine umuthi womugqa wokuqala ekwelapheni ukuwohloka komqondo ohambisana nesifo i-Alzheimer futhi okwamanje uyamakethwa emhlabeni wonke.

LOKHO ONGAKUTHATHE KULESI SIHLOKO:

Progression of new drug development in the field of Alzheimer’s disease is relatively slow, and at present there are only a very limited number of therapeutic options available to patients.
Luye Pharma also plans to accelerate the marketing of Rivastigmine MD in a number of developing countries and emerging markets around the world.
Rivastigmine is a first-line drug in the treatment of dementia associated with Alzheimer’s disease and is currently marketed worldwide.